| Bioactivity | Efinaconazole (KP-103) is a triazole antifungal agent and againsts T. mentagrophytes SM-110 and C. albicans ATCC 10231 with MICs of 0.0039 μg/mL and 0.00098 μg/mL, respectively[1]. Efinaconazole has a potent in vitro activity against fungal pathogens including dermatophytes, Candida and Malassezia species[1]. | ||||||||||||
| Target | Fungal | ||||||||||||
| In Vivo | Topical Efinaconazole solution (0.25 to 1%) is dose-dependently effective in treating both dermatophytoses, for 10 guinea pigs with interdigital tinea pedis or tinea corporis is investigated. The follow up study performs on day-30 and day-9 posttreatment demonstrated that the relapse rates for 1% Efinaconazole-treated animals with tinea pedis and for those with tinea corporis are 20 and 30%, respectively. When a single dose of 1% Efinaconazole is applied to the back skin 48 hours before fungal inoculation, 9 of the 10 animals are protected from the dermatophytosis, suggesting that active Efinaconazole is retained in skin tissue for at least 48 hours after dosing[2]. | ||||||||||||
| Name | Efinaconazole | ||||||||||||
| CAS | 164650-44-6 | ||||||||||||
| Formula | C18H22F2N4O | ||||||||||||
| Molar Mass | 348.39 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Tatsumi Y, et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother. 2013 May;57(5):2405-9. [2]. Tatsum Y, et al. KP-103, a novel triazole derivative, is effective in preventing relapse and successfully treating experimental interdigital tinea pedis and tinea corporis in guinea pigs. Microbiol Immunol. 2002;46(7):425-32. |
Efinaconazole
CAS: 164650-44-6 F: C18H22F2N4O W: 348.39
Efinaconazole (KP-103) is a triazole antifungal agent and againsts T. mentagrophytes SM-110 and C. albicans ATCC 10231 w
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.